Department of Histology, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.
Department of Public Health, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.
Asian Pac J Cancer Prev. 2022 Jun 1;23(6):2001-2008. doi: 10.31557/APJCP.2022.23.6.2001.
Liver cirrhosis and hepatocellular carcinoma (HCC) are chronic liver diseases that can cause serious health problems. Meanwhile, the methods used to detect liver cirrhosis and HCC are limited. Apolipoprotein A1 (ApoA1) is a protein that makes up high-density lipoprotein (HDL), which plays a role in liver cirrhosis and HCC, and can be used as a biomarker. This study aims to determine the ability of ApoA1 to detect and differentiate liver cirrhosis and hepatocellular carcinoma.
This cross-sectional study was conducted on 47 patients with liver cirrhosis and HCC at Margono Soekarjo Regional General Hospital, Purwokerto, Indonesia. This study also involved 33 healthy participants from blood donors at the Blood Transfusion Unit, Indonesian Red Cross, Banyumas. Serum ApoA1 levels were analyzed by ELISA method. Receiver Operating Characteristics (ROC) were used to evaluate the diagnostic power of ApoA1 and differentiate between cirrhotic, HCC, and healthy patients. Multivariate binary logistic regression test to determine the most influential variables on the incidence of cirrhosis, HCC, and health.
ApoA1 was able to differentiate cirrhosis from HCC, cirrhosis from healthy and HCC from healthy, with sensitivity 56.7%, 86.7%, 70.6%, specificity 70.6%, 93.9%, 84.9%, respectively, and AUC 68.5%, 92.6%, 75.0%. AFP (p = 0.002, OR 1.004) and bilirubin (p = 0.021, OR 1.259) were variables that contributed to cirrhosis - HCC. Age (p = 0.011, OR 0.766) and AST (p = 0.003, OR 0.834) are variables that play a role in health - cirrhosis. ALT (p = 0.024, OR 0.965) and PT (p = 0.004, OR 0.253) are variables that play a role in healthy - HCC.
ApoA1 was best for detecting healthy from cirrhosis, followed by healthy from HCC and cirrhosis from HCC. ApoA1 is not the primary variable determining the incidence of cirrhosis - HCC, healthy - HCC, and healthy - HCC.
肝硬化和肝细胞癌(HCC)是慢性肝病,可导致严重的健康问题。同时,用于检测肝硬化和 HCC 的方法有限。载脂蛋白 A1(ApoA1)是一种构成高密度脂蛋白(HDL)的蛋白质,在肝硬化和 HCC 中起作用,可作为生物标志物。本研究旨在确定 ApoA1 检测和区分肝硬化和肝细胞癌的能力。
本横断面研究在印度尼西亚万隆班尤马萨克罗贾科地区综合医院对 47 名肝硬化和 HCC 患者进行,同时还纳入了来自献血者的 33 名健康参与者,他们是印尼红十字会血液科的献血者。通过 ELISA 法分析血清 ApoA1 水平。受试者工作特征(ROC)曲线用于评估 ApoA1 的诊断能力,并区分肝硬化、HCC 和健康患者。多变量二项逻辑回归检验确定对肝硬化、HCC 和健康发生影响最大的变量。
ApoA1 能够区分肝硬化与 HCC、肝硬化与健康、HCC 与健康,其灵敏度分别为 56.7%、86.7%、70.6%,特异性分别为 70.6%、93.9%、84.9%,AUC 分别为 68.5%、92.6%、75.0%。AFP(p=0.002,OR 1.004)和胆红素(p=0.021,OR 1.259)是导致肝硬化-HCC 的变量。年龄(p=0.011,OR 0.766)和 AST(p=0.003,OR 0.834)是健康-肝硬化的变量。ALT(p=0.024,OR 0.965)和 PT(p=0.004,OR 0.253)是健康-HCC 的变量。
ApoA1 最适合检测健康与肝硬化,其次是健康与 HCC 和肝硬化与 HCC。ApoA1 不是决定肝硬化-HCC、健康-HCC 和健康-HCC 发生的主要变量。